Wechselwirkungen · Wezenla
WEZENLA 45 mg solution for injection WEZENLA 45 mg solution for injection in pre-filled syringe WEZENLA 90 mg solution for injection in pre-filled syringe · Abschnitt 4.5 · PDF-Seite 28
HOS-151627 · Präparat HOS-100575
In psoriasis studies, the safety and efficacy of ustekinumab in combination with immunosuppressants, including biologics, or phototherapy have not been evaluated. In psoriatic arthritis studies, concomitant MTX use did not appear to influence the safety or efficacy of ustekinumab. In Crohn’s disease and ulcerative colitis studies, concomitant use of immunosuppressants or corticosteroids did not appear to influence the safety or efficacy of ustekinumab (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-16T11:50:00Z · SHA-256 ee8a4a8f48f02ce6abe6b0d6d8b9c74092ca858a6dbb9266fd0c8cbbf48dea12 · Passage ae405825133c27887a6b643b9f7b882b2442ac399cf5b6ed7a89237193cca321 · Zeichen 1746–2220 im Abschnitt